Mom classroom ! free gift for you ![ Online Registration ]
0800-208-088
中文
0800-208-088
中文

Quality & Trust
Serum-free culture medium
Exclusive U.S. Patents and a new page in the history of stem cell research in Taiwan


Patent No. : US 8762074 B2
Recent development in regenerative medicine has sparked interests among parents on the storage of umbilical cord blood stem cells. Due to insufficient quantities of cord blood stem cells, people have been doubtful and questioned the necessity of cryopreserving cord blood for the baby. Nowadays with Sino Cell’s ex vivo stem cell expansion technology, there are finally innovative results in stem cell cryopreservation. After a decade of constant research and development lead by Dr. Shiaw-Ming Huang for FIRDI and Dr. Chao-Ling Yau, Sino Cell have at last passed through the complicated processes and trials of the United States Patents and obtained the U.S. Patent for serum-free culture medium (Optimizing Culture Medium for CD34 Hematopoietic Cell Expansion) in 2014. Unlike the traditional cord blood culturing and preservation methods, now the quantity of hematopoietic stem cells can be increased by 30 folds in just 7 days, which not only eliminates the past limitation of 30kg body weight of the patient, but also benefits more patients significantly with the availability of cord blood storage.
 
Serum-free culture medium for HSC

The serum-free expansion medium for HSC can be used for HSC of various sources. It has the advantages of serum-free, no need for feeder layer cells and low cytokine level, and can successfully increase the HSC by 30 folds or more in just 7 days, satisfying the clinical requirement of the CD34 HSC count for transplantation of adult patients.

After one-week culture, the expansions for WBC and
CD34 cells were 64- and 27-fold, respectively.
Globalized cryopreservation of cord blood units (CBU) and for protection across borders
Collaboration between Taiwan and Japan – professionalism and quality recognized by Japan

The Yoshida couple has been assigned to Taiwan for work over a decade ago. While the Yoshidas wish to preserve the cord blood for their expecting baby, the husband is going to be assigned back to Japan, and circumstances do not allow them to have their baby in Japan. Seeking consultation, they contacted the Stem Cell Institute Inc. at Tokyo, Japan. Professor Oono Tsuneya, CEO of Stem Cell Institute Inc. at the time, has already collaborated with Sino Cell on many technology exchanges, and has praised highly of Sino Cell’s international level preservation service. Therefore, he advised the Yoshidas to have Sino Cell cryostore their baby’s cord blood stem cells, and to apply for usage when needed.

When the child of Yoshidas has reached 10 years of age, they filed application with the Stem Cell Institute Inc. to transport their Taiwan-stored cord blood stem cells back to Japan. After receiving Yoshida’s application, Sino Cell filed an official application for the exportation of cord blood stem cells with Taiwan’s Ministry of Health and Welfare, and received MOHW’s approval letter on June 30, 3011. On October 17, 2011, the cord blood stem cells was picked up from the bank and delivered to Japan’s Stem Cell Institute Inc., completing an industry-rare case of cross-border collaboration.

Sino Cell opens the door for oversea delivery service

In 2010, the Lien Sheng-Wu couple, who had given birth in Hong Kong, applied for overseas delivery service with Sino Cell to transport their baby’s cord blood, umbilical cord, and amniotic membrane back to Taiwan. Since this is a case of overseas importation, Sino Cell made a comprehensive evaluation and filed an application with the MOHW as per regulation. After obtaining the approval, Sino Cell completed the collection of cord blood and tissues in 36 hours, and completed the isolation and storage of stem cells in 48 hours. This case also paved the way for future oversea delivery service.

 
Professional and global certifications
Most professional protection guaranteed for the stored cord blood products and future transplantation application
  1. ISO 9001:2008 Certificate
  2. Taiwan Accreditation Foundation (TAF) National Certificate
  3. Passed the Ministry of Health and Welfare’s review for Human Organ Bank
  4. Certificate for Symbol of National Quality
  1. Certificate of Participating Proficiency Testing 2015, from Taiwan Society of Laboratory Medicine
  2. Laboratory certificate from the U.S. College of American Pathologists (CAP)
  3. National Innovation Award
  4. Certificate for nomination of the National Biotechnology & Medical Care Quality Award